BR112023024646A2 - Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina - Google Patents

Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina

Info

Publication number
BR112023024646A2
BR112023024646A2 BR112023024646A BR112023024646A BR112023024646A2 BR 112023024646 A2 BR112023024646 A2 BR 112023024646A2 BR 112023024646 A BR112023024646 A BR 112023024646A BR 112023024646 A BR112023024646 A BR 112023024646A BR 112023024646 A2 BR112023024646 A2 BR 112023024646A2
Authority
BR
Brazil
Prior art keywords
compound
medicine
preparation
application
same
Prior art date
Application number
BR112023024646A
Other languages
English (en)
Portuguese (pt)
Inventor
Feng He
Feng Shen
Huaide Dong
Weikang Tao
Xin Li
Yang Chen
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of BR112023024646A2 publication Critical patent/BR112023024646A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BR112023024646A 2021-06-21 2022-06-21 Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina BR112023024646A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110687643 2021-06-21
CN202110880105 2021-08-02
CN202111073775 2021-09-14
CN202111225928 2021-10-21
PCT/CN2022/100016 WO2022268051A1 (zh) 2021-06-21 2022-06-21 稠合四环类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
BR112023024646A2 true BR112023024646A2 (pt) 2024-03-05

Family

ID=84544976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024646A BR112023024646A2 (pt) 2021-06-21 2022-06-21 Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina

Country Status (11)

Country Link
US (1) US20240327434A1 (https=)
EP (1) EP4361157A4 (https=)
JP (1) JP2024522766A (https=)
KR (1) KR20240024903A (https=)
CN (1) CN117255793A (https=)
AU (1) AU2022297474A1 (https=)
BR (1) BR112023024646A2 (https=)
CA (1) CA3220929A1 (https=)
MX (1) MX2023015533A (https=)
TW (1) TW202317587A (https=)
WO (1) WO2022268051A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3210167A1 (en) * 2021-02-09 2022-08-18 Genentech, Inc. Tetracyclic oxazepine compounds and uses thereof
CA3211725A1 (en) * 2021-03-17 2022-09-22 Tao Jiang Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
AU2022303440A1 (en) * 2021-07-02 2024-02-22 Shanghai De Novo Pharmatech Co., Ltd. Kras g12d inhibitor and use thereof
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
US20250034166A1 (en) * 2021-09-27 2025-01-30 Jacobio Pharmaceuticals Co., Ltd. Polycyclic fused ring derivatives and use thereof
EP4471037A1 (en) * 2022-01-30 2024-12-04 Shanghai Pharmaceuticals Holding Co., Ltd. Quinoline compound and use thereof
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
CR20240508A (es) * 2022-05-19 2024-12-20 Genentech Inc Compuestos aza-tetracíclicos de oxazepina y usos de los mismos
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
CN119790058A (zh) * 2022-07-09 2025-04-08 荣山医药股份有限公司 用于治疗疾病的稠合环kras抑制剂
WO2024022444A1 (zh) * 2022-07-27 2024-02-01 江苏恒瑞医药股份有限公司 稠环类化合物、其制备方法及其在医药上的应用
AU2023314335A1 (en) * 2022-07-29 2025-02-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising kras g12d inhibitor
CN119585278A (zh) * 2022-08-05 2025-03-07 杭州中美华东制药有限公司 具有KRas G12D抑制作用的化合物
IL318647A (en) 2022-08-05 2025-03-01 Kumquat Biosciences Inc Heterocyclic compounds and their uses
WO2024041573A1 (en) * 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
TW202426459A (zh) * 2022-09-23 2024-07-01 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
AU2023388747A1 (en) * 2022-12-07 2025-07-10 Jacobio Pharmaceuticals Co., Ltd. Fused cyclic compounds and use thereof
EP4640689A1 (en) * 2022-12-20 2025-10-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal form of kras g12d inhibitor and preparation method therefor
WO2024149214A1 (en) * 2023-01-10 2024-07-18 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
WO2024234360A1 (en) * 2023-05-18 2024-11-21 Nikang Therapeutics , Inc. Tetracyclic derivatives as kras inhibitors
WO2024159471A1 (en) * 2023-02-02 2024-08-08 Nikang Therapeutics , Inc. Tetracyclic derivatives as kras inhibitors
KR20260041941A (ko) 2023-03-15 2026-03-27 콴타 테라퓨틱스, 인크. Kras 조절 인자 및 이의 용도
WO2024208305A1 (zh) * 2023-04-07 2024-10-10 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
EP4695262A1 (en) * 2023-04-10 2026-02-18 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) * 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
AU2024306338A1 (en) * 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
CN121399088A (zh) 2023-07-13 2026-01-23 上海森辉医药有限公司 Kras g12d中间体的制备方法
TW202517649A (zh) * 2023-07-18 2025-05-01 大陸商泰勵生物科技（上海）有限公司 具有抗ｋｒａｓ突變腫瘤活性的化合物
WO2025045141A1 (en) * 2023-08-31 2025-03-06 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024374420A1 (en) * 2023-11-02 2026-04-16 Kumquat Biosciences Inc. Degraders and uses thereof
WO2025108443A2 (en) * 2023-11-23 2025-05-30 Beigene Switzerland Gmbh Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2025146194A1 (en) * 2024-01-05 2025-07-10 Jacobio Pharmaceuticals Co., Ltd. Fused tetracyclic compounds and use thereof
WO2025153038A1 (en) * 2024-01-17 2025-07-24 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
CN119684315A (zh) * 2024-01-26 2025-03-25 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
WO2025157261A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物晶型及其制备方法
CN119661556B (zh) * 2024-01-26 2025-12-09 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
CN119490512A (zh) * 2024-01-26 2025-02-21 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
EP3621968A1 (en) * 2017-05-11 2020-03-18 Astrazeneca AB Heteroaryl compounds that inhibit g12c mutant ras proteins
US10745385B2 (en) * 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
TW202110837A (zh) 2019-05-24 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
WO2021000885A1 (zh) * 2019-07-01 2021-01-07 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
MX2022002465A (es) * 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CA3210167A1 (en) * 2021-02-09 2022-08-18 Genentech, Inc. Tetracyclic oxazepine compounds and uses thereof
US20240199644A1 (en) * 2021-03-07 2024-06-20 Jacobio Pharmaceuticals Co., Ltd. Fused Ring Derivatives Useful as KRAS G12D Inhibitors
CA3211725A1 (en) * 2021-03-17 2022-09-22 Tao Jiang Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
WO2022199587A1 (zh) * 2021-03-24 2022-09-29 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
CN116113632B (zh) * 2021-03-30 2025-08-29 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
AU2022303440A1 (en) * 2021-07-02 2024-02-22 Shanghai De Novo Pharmatech Co., Ltd. Kras g12d inhibitor and use thereof
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
CN116323625A (zh) * 2021-08-25 2023-06-23 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
EP4471037A1 (en) * 2022-01-30 2024-12-04 Shanghai Pharmaceuticals Holding Co., Ltd. Quinoline compound and use thereof
CR20240451A (es) * 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
CR20240508A (es) * 2022-05-19 2024-12-20 Genentech Inc Compuestos aza-tetracíclicos de oxazepina y usos de los mismos

Also Published As

Publication number Publication date
EP4361157A4 (en) 2024-10-16
CN117255793A (zh) 2023-12-19
AU2022297474A1 (en) 2024-01-18
KR20240024903A (ko) 2024-02-26
US20240327434A1 (en) 2024-10-03
WO2022268051A1 (zh) 2022-12-29
MX2023015533A (es) 2024-01-23
CA3220929A1 (en) 2022-12-29
TW202317587A (zh) 2023-05-01
JP2024522766A (ja) 2024-06-21
EP4361157A1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
BR112023024646A2 (pt) Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina
MX2025001020A (es) Compuesto de anillo fusionado, metodo de preparacion del mismo y su aplicacion medicinal
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112022013009A2 (pt) Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
AR096203A1 (es) Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
BR112023022496A2 (pt) Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112022010360A2 (pt) Fármacos conjugados de polietilenoglicol ou um sal farmaceuticamente aceitável dos mesmos, intermediários e métodos para preparar os ditos fármacos, composição farmacêutica compreendendo os mesmos e uso terapêutico dos mesmos
BR112022013322A2 (pt) Derivado de tetra-hidroisoquinolina tricíclico, método de preparação para o mesmo e aplicação do mesmo em medicina
BR112022008000A2 (pt) Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112016002342A2 (pt) Microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica
BR112021022889A8 (pt) Derivados heterocíclicos fundidos, seus usos, composição farmacêutica e produto compreendendo os mesmos e método para a preparação dos mesmos
MX2023011166A (es) Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo